European Commission approves Astellas' XTANDI™ (Enzalutamide) for expanded use in recurrent early-stage prostate cancer treatment.

CSL Vifor and Travere Therapeutics Report European Commission's Approval of FILSPARI® (sparsentan) for IgA Nephropathy Treatment.

OncoC4 Reveals FDA Approval for Investigational New Drug Application of Its Unique SIGLEC 10 Immune Checkpoint Blocker, ONC-841, Targeting Solid Tumors.

hC Bioscience Reveals Primary Project in Hemophilia and Shares Encouraging Early Results from Innovative Protein Modification Strategy Using Engineered tRNA Anticodons.

Alto Neuroscience revealed encouraging initial outcomes for ALTO-101, a new PDE4 inhibitor, aimed at treating schizophrenia.

Hanmi Pharmaceutical will start a phase 1 clinical trial to evaluate the safety and effectiveness of its cancer immunotherapy, ‘BH3120’, in combination with MSD's KEYTRUDA® (pembrolizumab).

BeiGene, Ltd. disclosed that tislelizumab has received approval from the European Commission for use in treating non-small cell lung cancer.

ITM, Helmholtz Munich, and University Hospital Münster Report Initial Dosing of First Participant in Phase I Research Trial for Glioblastoma.

GPCRs, as key signal transduction molecules on the cell surface, regulate various physiological processes and constitute one-third of the targets for clinical drug applications.

Voydeya has been sanctioned in the EU as a supplementary treatment alongside ravulizumab or eculizumab for adults with PNH who still suffer from persistent haemolytic anaemia.

LD50 (median lethal dose) is a commonly used indicator in toxicology to describe the toxicity of toxic substances or radiation.

The recent phase 3 LUNA 3 trial demonstrated that 400 mg of rilzabrutinib taken orally twice daily effectively achieved the primary goal of sustaining platelet response in adults with persistent or chronic immune thrombocytopenia.